1. |
Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase Ⅲ ranibizumab clinical trials[J]. Ophthalmology, 2011, 118:523-530.
|
2. |
Mariani A, Deli A, Ambresin A, et al. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration[J]. Graefe's Arch Clin Exp Ophthalmol, 2011, 249:1635-1642.
|
3. |
Hwang JC, Del Priore LV, Freund KB, et al. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration[J]. Ophthalmic Surg Lasers Imaging, 2011, 42:6-11.
|
4. |
Jo YJ, Sonoda KH, Oshima Y, et al. Establishment of a new animal model of focal subretinal fibrosis that resembles disciform lesion in advanced age-related macular degeneration[J]. Invest Ophthalmol Vis Sci, 2011, 52:6089-6095.
|
5. |
Friedlander M. Fibrosis and diseases of the eye[J]. J Clin Invest, 2007, 117:576-586.
|
6. |
Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective[J]. Mol Vis, 2003, 9:747-755.
|
7. |
Liu J, Jha P, Lyzogubov VV, et al. Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2(CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization[J]. J Biol Chem, 2011, 286:20991-21001.
|
8. |
Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease[J]. N Engl J Med, 2000, 342:1350-1358.
|
9. |
Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye[J]. J Clin Invest, 1989, 83:1661-1666.
|
10. |
Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration[J]. Surv Ophthalmol, 1992, 36:373-384.
|
11. |
Tanihara H, Yoshida M, Matsumoto M, et al. Identification of transforming growth factor-beta expressed in cultured human retinal pigment epithelial cells[J]. Invest Ophthalmol Vis Sci, 1993, 34:413-419.
|
12. |
Grotendorst GR, Smale G, Pencev D. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils[J]. J Cell Physiol, 1989, 140:396-402.
|
13. |
Li H, Wang H, Wang F, et al. Snail involves in the transforming growth factor beta1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells[J/OL]. PLoS One, 2011, 6:23322[2011-08-10].http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023322.
|
14. |
Zhang H, Liu ZL. Transforming growth factor-beta neutralizing antibodies inhibit subretinal fibrosis in a mouse model[J]. Int J Ophthalmol, 2012, 5:307-311.
|
15. |
Wynn TA. Cellular and molecular mechanisms of fibrosis[J]. J Pathol, 2008, 214:199-210.
|
16. |
Ma Y, Tao Y, Lu Q, et al. Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2011, 152:678-685.
|
17. |
Symeonidis C, Papakonstantinou E, Androudi S, et al. Interleukin-6 and matrix metalloproteinase expression in the subretinal fluid during proliferative vitreoretinopathy: correlation with extent, duration of RRD and PVR grade[J]. Cytokine, 2012, 59:184-190.
|
18. |
Izumi-Nagai K, Nagai N, Ozawa Y, et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3(STAT3) promotes choroidal neovascularization[J]. Am J Pathol, 2007, 170:2149-2158.
|
19. |
Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction[J]. Invest Ophthalmol Vis Sci, 2000, 41:1210-1216.
|
20. |
Ricker LJ, Kijlstra A, Kessels AG, et al. Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study[J/OL]. PLoS One, 2011, 6:19141[2011-08-27].http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0019141.
|